Bioactivation and reactivity research advances – 2021 year in review





Citation of Original Publication

Klarissa D. Jackson, Upendra A. Argikar, Sungjoon Cho, Rachel D. Crouch, James P. Driscoll, Carley J. S. Heck, Lloyd King, Hlaing (Holly) Maw, Grover P. Miller, Herana Kamal Seneviratne, Shuai Wang, Cong Wei, Donglu Zhang & S. Cyrus Khojasteh (2022) Bioactivation and reactivity research advances – 2021 year in review, Drug Metabolism Reviews, 54:3, 246-281, DOI: 10.1080/03602532.2022.2097254


This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)



This year’s review on bioactivation and reactivity began as a part of the annual review on biotransformation and bioactivation led by Cyrus Khojasteh (see references). Increased contributions from experts in the field led to the development of a stand alone edition for the first time this year focused specifically on bioactivation and reactivity. Our objective for this review is to highlight and share articles which we deem influential and significant regarding the development of covalent inhibitors, mechanisms of reactive metabolite formation, enzyme inactivation, and drug safety. Based on the selected articles, we created two sections: (1) reactivity and enzyme inactivation, and (2) bioactivation mechanisms and safety (Table 1). Several biotransformation experts have contributed to this effort from academic and industry settings.